There has also been movement recently on a new form of treatment for COVID-19: monoclonal antibodies.
Monoclonal antibodies are laboratory created antibodies specifically designed to help fight off COVID-19.
“These are antibodies that are similar to the ones your body would naturally make in response to infection. However, monoclonal antibodies are mass-produced in a laboratory and are designed to recognize a specific component of this virus — the spike protein on its outer shell.
By targeting the spike protein, these specific antibodies interfere with the virus’ ability to attach and gain entry into human cells. They give the immune system a leg up until it can mount its own response,” Dr. Howard J. Huang, medical director of the Houston Methodist Lung Transplant Center, said.
The FDA has also gotten on-board with the treatment through its emergency use authorization program.8
Generally, the treatment is most effective at the beginning stages of COVID-19. The FDA says the monoclonal antibody cocktail “was shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.”9
Typically, these treatments are given in infusion centers.
Like any other IV therapy treatment, there exists the chance for complications such as infiltration, extravasation, and phlebitis.
MORE: IV Infiltration and Extravasation: Causes, Signs, Side Effects, and Treatment
At the end of the day, it remains important to listen to your healthcare team when it comes to treating COVID-19.